We are live on ! Find out more
ITOS

iTeos Therapeutics
ITOS

Delisted

ITOS was delisted on the 28th of August, 2025.

Back to rankings

77 hedge funds and large institutions have $841M invested in iTeos Therapeutics in 2021 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 27 increasing their positions, 25 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more funds holding in top 10

Funds holding in top 10: 3 → 4 (+1)

12% more capital invested

Capital invested by funds: $754M → $841M (+$87.7M)

4.52% more ownership

Funds ownership: 83.95% → 88.47% (+4.5%)

8% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 25

7% less funds holding

Funds holding: 83 → 77 (-6)

33% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 18

Holders
77
Holders Change
-6
Holders Change %
-7.23%
% of All Funds
1.35%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.07%
New
12
Increased
27
Reduced
25
Closed
18
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
RCMNY
Rubric Capital Management (New York)
New York
+$25.8M
2
TCM
Tang Capital Management
California
+$17.8M
3
RI
RTW Investments
New York
+$16.6M
4
EC
EcoR1 Capital
California
+$6.99M
5
SAM
Sectoral Asset Management
Quebec, Canada
+$6.95M

Top Sellers

Rank Fund Capital Flow
1
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$27.1M
2
MAM
MPM Asset Management
Massachusetts
-$9.81M
3
MB
MPM BioImpact
Massachusetts
-$6.05M
4
MWNA
Marshall Wace North America
New York
-$4.68M
5
Marshall Wace
Marshall Wace
United Kingdom
-$2.26M
Name Holding Trade Value Shares
Change 		Change in
Stake
US Bancorp
76
US Bancorp
Minnesota
$3K +$3.01K +115 New
Janus Henderson Group
77
Janus Henderson Group
United Kingdom
– -$27.1M -1,056,545 Closed
Susquehanna International Group
78
Susquehanna International Group
Pennsylvania
– -$691K -26,939 Closed
Jacobs Levy Equity Management
79
Jacobs Levy Equity Management
New Jersey
– -$672K -26,205 Closed
TI
80
Trexquant Investment
Connecticut
– -$661K -25,778 Closed
Tudor Investment Corp
81
Tudor Investment Corp
Connecticut
– -$654K -25,485 Closed
AAA
82
Affinity Asset Advisors
New York
– -$641K -25,000 Closed
Squarepoint
83
Squarepoint
New York
– -$603K -23,504 Closed
JF
84
Jump Financial
Illinois
– -$504K -19,658 Closed
PL
85
Parkwood LLC
Ohio
– -$484K -18,859 Closed
HF
86
HRT Financial
New York
– -$367K -14,315 Closed
Russell Investments Group
87
Russell Investments Group
United Kingdom
– -$343K -13,399 Closed
Millennium Management
88
Millennium Management
New York
– -$266K -10,389 Closed
Arrowstreet Capital
89
Arrowstreet Capital
Massachusetts
– -$245K -9,560 Closed
CPIG
90
Chicago Partners Investment Group
Illinois
– -$228K -9,325 Closed
Principal Financial Group
91
Principal Financial Group
Iowa
– -$208K -8,090 Closed
FC
92
FORA Capital
Florida
– -$96K -3,740 Closed
LC
93
Lindbrook Capital
California
– -$26K -1,000 Closed
S
94
SignatureFD
Georgia
– -$1K -30 Closed
SOW
95
State of Wyoming
Wyoming
– -$105 -4 -31%
1 2 3
4

ITOS Hedge Fund Activity: Q3 2021 in Review

77 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in iTeos Therapeutics (ITOS) for Q3 2021, worth a combined $841M — up 12% from $754M a quarter earlier.

Sellers outnumbered buyers: 18 funds closed out of ITOS and 12 opened new positions — a net loss of 6 holders — while 25 trimmed existing stakes and 27 added.

The largest buyer was Rubric Capital Management (New York), opening a new position worth an estimated $25.8M. The largest seller was Janus Henderson Group, exiting entirely with an estimated $27.1M sold.

  • 77 institutional investors held iTeos Therapeutics (ITOS) as of Q3 2021, down from 83 in Q2 2021.
  • Funds reported $841M of iTeos Therapeutics stock for Q3 2021, up 12% quarter-over-quarter.
  • 12 funds opened new iTeos Therapeutics positions in Q3 2021 and 18 closed out, a net change of -6 holders.
  • The largest iTeos Therapeutics buyer in Q3 2021 was Rubric Capital Management (New York), an estimated $25.8M added.
  • The largest iTeos Therapeutics seller in Q3 2021 was Janus Henderson Group, an estimated $27.1M sold.

Based on aggregated 13F filings for Q3 2021.